← Leaderboards
Graca Duarte Almeida-Porada
Wake Forest University Health Sciences
$10,981,686
Attributed
$18,716,856
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,716,856 · 11
By mechanism
R01$15,239,868 · 8
TL1$2,479,467 · 1
U01$769,518 · 1
R21$228,003 · 1
Top collaborators
- Christopher D Porada20 shared
- Steven D Crowley6 shared
- Susan L Hogan6 shared
- Shay Soker2 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- James C. Rose$15,077,307
- Christopher D Porada$6,964,841
- Michael A Thomas$604,761
- Jorge Pablo Figueroa$5,892,821
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsSheepLifeImmuneAnimal ModelCell TypeBone MarrowSafetyEngraftmentHemophilia ABirthAnimalsTransgenesVectorF8 GeneProteinsFetalInheritedHematopoietic Stem CellsIn VivoAdultPhenotypeDoseIncidence
Grant awards (40)
TRIO NRSA Training Core$711,244
TL1 · FY2025 · DK
Targeted conditioning to maximize prenatal HSC engraftment for SCD$665,070
R01 · FY2025 · HL · contact PI
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$652,874
R01 · FY2025 · HL · contact PI
Using human liver tissue equivalents to optimize AAV-mediated GT and better define age-related clinical risks$383,800
R01 · FY2025 · HL · contact PI
TRIO NRSA Training Core$160,023
TL1 · FY2025 · DK
TRIO NRSA Training Core$49,901
TL1 · FY2025 · DK
TRIO NRSA Training Core$767,246
TL1 · FY2024 · DK
Targeted conditioning to maximize prenatal HSC engraftment for SCD$662,949
R01 · FY2024 · HL · contact PI
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$648,076
R01 · FY2024 · HL · contact PI
Using human liver tissue equivalents to optimize AAV-mediated GT and better define age-related clinical risks$383,921
R01 · FY2024 · HL · contact PI
Pre-doctoral Diversity Supplement to TLDK139567$49,292
TL1 · FY2024 · DK
TRIO NRSA Training Core$741,761
TL1 · FY2023 · DK
Targeted conditioning to maximize prenatal HSC engraftment for SCD$716,640
R01 · FY2023 · HL · contact PI
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$673,905
R01 · FY2023 · HL · contact PI
Using human liver tissue equivalents to optimize AAV-mediated GT and better define age-related clinical risks$397,789
R01 · FY2023 · HL · contact PI
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$707,639
R01 · FY2022 · HL · contact PI
Prenatal Cell and Gene Therapy for Hemophilia A$698,903
R01 · FY2020 · HL · contact PI
cGMP Manufacture Of FVIII-Expressing Placental Cells For Hemophilia A$383,839
U01 · FY2020 · HL · contact PI
Prenatal Cell and Gene Therapy for Hemophilia A$692,734
R01 · FY2019 · HL · contact PI
Postnatal Cell-Based Therapies for Hemophilia A$577,601
R01 · FY2019 · HL · contact PI
cGMP Manufacture Of FVIII-Expressing Placental Cells For Hemophilia A$385,679
U01 · FY2019 · HL · contact PI
Prenatal Cell and Gene Therapy for Hemophilia A$675,825
R01 · FY2018 · HL · contact PI
Postnatal Cell-Based Therapies for Hemophilia A$577,601
R01 · FY2018 · HL · contact PI
Prenatal Cell and Gene Therapy for Hemophilia A$746,740
R01 · FY2017 · HL · contact PI
Postnatal Cell-Based Therapies for Hemophilia A$606,184
R01 · FY2017 · HL · contact PI
Postnatal Cell-Based Therapies for Hemophilia A$698,612
R01 · FY2016 · HL · contact PI
Cord Blood Expansion Inside a Bioengineered Liver$113,190
R21 · FY2014 · HL · contact PI
Cord Blood Expansion Inside a Bioengineered Liver$114,813
R21 · FY2013 · HL · contact PI
Functional Analysis of the Hematopoietic Niche during Ontogeny$366,300
R01 · FY2012 · HL · contact PI
Functional Analysis of the Hematopoietic Niche during Ontogeny$350,502
R01 · FY2011 · HL · contact PI
Functional Analysis of the Hematopoietic Niche during Ontogeny$350,502
R01 · FY2010 · HL · contact PI
Functional Analysis of the Hematopoietic Niche during Ontogeny$350,502
R01 · FY2009 · HL · contact PI
In Utero Stem Cell Transplantation for Hemophilia A$443,822
R01 · FY2006 · HL · contact PI
In Utero Stem Cell Transplantation for Hemophilia A$455,143
R01 · FY2005 · HL
In Utero Stem Cell Transplantation for Hemophilia A$441,706
R01 · FY2004 · HL
Evaluation of Stem Cell Plasticity In Vivo$216,450
R01 · FY2004 · HL
In Utero Stem Cell Transplantation for Hemophilia A$448,728
R01 · FY2003 · HL
Evaluation of Stem Cell Plasticity In Vivo$216,450
R01 · FY2003 · HL
Evaluation of Stem Cell Plasticity In Vivo$216,450
R01 · FY2002 · HL
Evaluation of Stem Cell Plasticity In Vivo$216,450
R01 · FY2001 · HL